global leukemia therapeutics market size, share and forecast 2026 | techsci research
DESCRIPTION
According to #TechSci Research report, Global Leukemia Therapeutics Market is expected to grow at a formidable rate during the forecast period to reach USD7636.21 million on account of the increasing prevalence of leukemia. Report URL - https://bit.ly/3wfT1GO Visit our website @ https://www.techsciresearch.com/ For more market research news visit our blog: https://techsciblog.com/TRANSCRIPT
GLOBAL LEUKEMIA THERAPEUTICS MARKETFORECAST & OPPORTUNITIES
2016 – 2026
www.techsciresearch.comMARKET INTELLIGENCE . CONSULTING
Scope of ReportProduct of Interest (POI): Leukemia Therapeutics
Review Period
2016 – 2019
Base Year
2020
Estimated Year
2021
Forecast Period
2022 – 2026
Year Range
Leukemia, also spelled leukaemia, is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, fatigue, fever, and an increased risk of infections. Leukemia therapeutics refers to the treatment of leukemia using chemotherapy, stem cell transplantation, immunotherapy, targeted therapy and others.
2
Market Segmentation
TYPE
• Chronic Lymphocytic Leukemia• Acute Myeloid Leukemia• Chronic Myeloid Leukemia• Acute Lymphocytic Leukemia• Others
DIAGNOSIS
• Blood Test• Biopsy
• Physical Exam• Imaging
REGION
• Europe• North America• South America• Middle East & Africa• Asia Pacific
AGE GROUPS• 0-15• 15-30• 30-50• 50+
GENDER• Male• Female
TREATMENT• Chemotherapy• Stem Cell Transplantation• Immunotherapy• Targeted Therapy• Others
ROUTE OF ADMINISTRATION• Oral• Parenteral
DRUGS• Tyrosine Kinase Inhibitors• Antimetabolites• Hormones (Corticosteroids)• Monoclonal Antibodies• Others
S. No. Contents Page No.1. Product Overview (Definition of product and major terminologies used in the report)
2. Research Methodology (Detailed description of the methodology used to conduct the research, Raw data backup, list of all secondary sources, List of respondents for primary surveys)
3. Impact of COVID-19 on Global Leukemia Therapeutics Market4. Executive Summary (This chapter covers summary of the complete study.)5. Voice of Customer(Brand Awareness, Challenges Faced Post Purchase, Factors Influencing Purchase Decision)
5.1. Brand Awareness5.2. Factors driving Global Leukemic Therapeutics Market5.3. Unmet Needs and Challenges
6.Global Leukemia Therapeutics Market Outlook, 2016-2026F (This chapter includes a brief overview of the product of interest market such as total market’s growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.)6.1. Market Size & Forecast
6.1.1. By Value6.2. Market Share & Forecast
6.2.1. By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia,Acute Lymphocytic Leukemia, Others)
6.2.2. By Gender (Male, Female)6.2.3. By Age Groups (0-15, 15-30, 30-50, 50+)6.2.4. By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging)
6.2.5. By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy,Others)
6.2.6. By Drugs (Antimetabolites, Hormones (Corticosteroids), Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others)
6.2.7. By Route of Administration (Oral, Parenteral)6.2.8. By Company (2020)6.2.9. By Region
Table of Contents
3
Table of Contents
4
S. No. Contents Page No.7. Asia-Pacific Leukemia Therapeutics Market Outlook
1. Market Size & Forecast7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1.7.2.2.7.2.3.7.2.4.7.2.5.7.2.6.
By TypeBy Diagnosis By Treatment By DrugsBy Route of Administration By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Leukemia Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
Market Share & Forecast7.3.1.2.
7.3.1.2.1.7.3.1.2.2.
7.3.1.2.3.7.3.1.2.4.7.3.1.2.5.
By TypeBy DiagnosisBy Treatment By DrugsBy Route of Administration
S. No. Contents Page No.
7.3.2. India Leukemia Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By Treatment
7.3.2.2.4. By Drugs
7.3.2.2.5. By Route of Administr ation
7.3.3. Japan Leukemia Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By Treatment
7.3.3.2.4. By Drugs
7.3.3.2.5. By Route of Administr ation
Table of Contents
5
S. No. Contents Page No.
7.3.4. South Korea Leukemia Therapeutics Market O utlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Diagnosis
7.3.4.2.3. By Treatment
7.3.4.2.4. By Drugs
7.3.4.2.5. By Route of Administr ation
7.3.5. Australia Leukemia Therapeutics Market Outl ook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Diagnosis
7.3.5.2.3. By Treatment
7.3.5.2.4. By Drugs
7.3.5.2.5. By Route of Administr ation
Table of Contents
6
Table of Contents
7
S. No. Contents Page No.8. Europe Leukemia Therapeutics Market Outlook
1. Market Size & Forecast
8.1.1. By Value8.2. Market Share & Forecast
8.2.1.
8.2.2.8.2.3.8.2.4.
8.2.5.
8.2.6.
By Type
By Diagnosis
By Treatment
By DrugsBy Route of Administration By Country
8.3. Europe: Country Analysis
8.3.1. Spain Leukemia Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
Market Share & Forecast8.3.1.2.8.3.1.2.1.8.3.1.2.2.
8.3.1.2.3.
8.3.1.2.4.8.3.1.2.5.
By TypeBy Diagnosis By Treatment By Drugs
By Route of Administration
S. No. Contents Page No.
8.3.2. France Leukemia Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By Treatment
8.3.2.2.4. By Drugs
8.3.2.2.5. By Route of Administrat ion
8.3.3. Germany Leukemia Therapeutics Market Outloo k
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By Treatment
8.3.3.2.4. By Drugs
8.3.3.2.5. By Route of Administrat ion
Table of Contents
8
S. No. Contents Page No.
8.3.4. United Kingdom Leukemia Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By Treatment
8.3.4.2.4. By Drugs
8.3.4.2.5. By Route of Administrat ion
8.3.5. Italy Leukemia Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By Treatment
8.3.5.2.4. By Drugs
8.3.5.2.5. By Route of Administrat ion
Table of Contents
9
Table of Contents
10
S. No. Contents Page No.9. North America Leukemia Therapeutics Market Outlook
1. Market Size & Forecast9.1.1. By Value
9.2. Market Share & Forecast9.2.1.9.2.2.9.2.3.9.2.4.9.2.5.9.2.6.
By TypeBy DiagnosisBy Treatment By DrugsBy Route of Administration By Country
3. North America: Country Analysis
1. United States Leukemia Therapeutics Market Outlook9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
Market Share & Forecast9.3.1.2.9.3.1.2.1.9.3.1.2.2.9.3.1.2.3.9.3.1.2.4.9.3.1.2.5.
By TypeBy Diagnosis By Treatment By DrugsBy Route of Administration
S. No. Contents Page No.
9.3.2. Mexico Leukemia Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Treatment
9.3.2.2.4. By Drugs
9.3.2.2.5. By Route of Administrati on
9.3.3. Canada Leukemia Therapeutics Market Outloo k
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Treatment
9.3.2.2.4. By Drugs
9.3.2.2.5. By Route of Administrati on
Table of Contents
11
Table of Contents
12
S. No. Contents Page No.10. South America Leukemia Therapeutics Market Outlook
10.1. Market Size & Forecast10.1.1. By Value
10.2. Market Share & Forecast10.2.1.10.2.2.10.2.3.10.2.4.10.2.5.10.2.6.
By TypeBy Diagnosis By Treatment By DrugsBy Route of Administration By Country
10.3. South America: Country Analysis
10.3.1. Brazil Leukemia Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast10.3.1.1.1 By Value
Market Share & Forecast10.3.1.2.10.3.1.2.1.10.3.1.2.2.10.3.1.2.3.10.3.1.2.4.10.3.1.2.5.
By TypeBy Diagnosis By Treatment By DrugsBy Route of Administration
Table of Contents
13
S. No. Contents Page No.10.3.2. Argentina Leukemia Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast10.3.2.1.1 By Value
Market Share & Forecast10.3.2.2.10.3.2.2.1.10.3.2.2.2.10.3.2.2.3.10.3.2.2.4.10.3.2.2.5.
By TypeBy Diagnosis By Treatment By DrugsBy Route of Administration10.3.3. Colombia Leukemia Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast10.3.3.1.1 By Value
Market Share & Forecast10.3.3.2.10.3.3.2.1.10.3.2.2.2.10.3.2.2.3.10.3.2.2.4.10.3.2.2.5.
By TypeBy Diagnosis By Treatment By DrugsBy Route of Administration11. Middle East & Africa Leukemia Therapeutics Market Outlook
11.1. Market Size & Forecast11.1.1. By Value
11.2. Market Share & Forecast11.2.1.11.2.2.
By TypeBy Diagnosis
Table of Contents
14
S. No. Contents Page No.11.2.3.
11.2.4.
11.2.5.
11.2.6.
By Treatment
By Drugs
By Route of Administration
By Country11.3. Middle East & Africa : Country Analysis
11.3.1. South Africa Leukemia Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
Market Share & Forecast11.3.1.2.
11.3.1.2.1.
11.3.1.2.2.
11.3.1.2.3.
By Type
By Diagnosis
By Treatment
By Drugs
By Route of Administration
11.3.1.2.4.
11.3.1.2.5.
11.3.2. Saudi Arabia Leukemia Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value & Volume
Market Share & Forecast11.3.2.2.
11.3.2.2.1. By Type
S. No. Contents Page No.11.3.2.2.2. By Diagnosis11.3.2.2.3. By Treatment11.3.2.2.4. By Drugs11.3.2.2.5. By Route of Ad ministration
11.3.3. UAE Leukemia Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast11.3.3.1.1. By Value & Vol ume
11.3.3.2. Market Share & Forecast11.3.3.2.1. By Type11.3.3.2.2. By Diagnosis11.3.3.2.3. By Treatment11.3.3.2.4. By Drugs11.3.3.2.5. By Route of Ad ministration
12. Market Dynamics (This chapter assesses the major demand drivers and restraints.)12.1. Drivers12.2. Challenges
13. Market Trends & Developments (This section captures recent trends pertaining to manufacturing or consumption, market movements in terms of points of production and consumption, advancements and development)14. Clinical Trial Analysis
15. Competitive Landscape
15.1. Competition Outlook15.2. Players Profiled (Leading Companies)
Table of Contents
15
S. No. Contents Page No.
15.1.1 Company Details
15.1.2. Products & Services
15.1.3. Products & Services
15.1.4. Key Market Focus & Geographical Presence
15.1.5. Recent Developments
15.1.6. Key Management Personnel
16. Strategic Recommendations (Based on the findings of the report strategic recommendations on how to enter andexpand market share)
17. About Us & Disclaimer
Table of Contents
16
RESEARCH METHODOLOGY
Research Methodology
Identifying Key Opinion Leaders
Questionnaire Design In-depth Interviews
Data Collection
Developing List of Respondents
Formulating Questionnaire
Market Profiling
Data Validation
Data Analysis
In-depth secondary research was conducted to determine top players in
the global leukemia therapeutics market,
overall market size and segmental market size.
In order to conduct industry experts’ interviews, TechSci formulated a detailed
discussion guide.
List of industry players and industry
specialists was developed.
TechSci conducted interviews with
industry experts and industry players for data collection and
verification.
Data obtained as a result of primary
and secondary research was
validated through rigorous
triangulation.
The data was scrutinized using MS-Excel, statistical
tools and internal proprietary database to obtain qualitative and
quantitative insights about the global leukemia therapeutics market.
Data Collection
Data Filter & Analysis
Research & Intelligence
Actionable Insights Business
Solution
Primary Research Desk Research Company Analysis
Recent Developments Market Changing
Aspects/Dynamics Government
Policies Conclusion
Market Participants Key Strengths
LinkedIn TechSci Internal
Database
Factiva Hoovers
Paid Sources
Company Websites Company Annual
Reports White Paper
Study Financial Reports Investor
Presentations Regulatory Body Associations, etc.
Secondary Research
Primary Research
18
Research Methodology
19
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of the global leukemia therapeutics
market. The team has analyzed the outlook of various segments of this market, while considering the major influencing
factors such as increasing awareness about leukemia therapeutics. The study includes market forecasting, which would
enable our clients to take better decisions while planning their strategy to achieve sustainability in the global leukemia
therapeutics market.
Methodology Followed for Calculation of Market Size:
• Market Size by Value & Volume : Market size, in terms of value, for the year 2020 was calculated based on information
collected through exhaustive secondary research and primary surveys, with various key opinion leaders/stakeholders,
such as Leukemia Therapeutics manufacturers, channel partners, market influencers & end users, industry experts, and
other industry participants.
• The team interviewed more than 15 – 20 leukemia therapeutics manufacturers, 100 – 120 end users, and 15 – 20 industry
experts and other value chain stakeholders in the global leukemia therapeutics market to obtain the overall market size
from 2016 to 2020, which was validated by the Delphi technique. Taking standard deviation into consideration, the market
size was averaged out, to arrive at the market size data during 2016-2020.
Research Methodology
20
• Respondents were asked about the current and future market growth rates, market shares by type, by gender, by age groups, by diagnosis,by treatment, by drugs, by route of administration, by company and by each region. Removing the outlier responses, the geometric mean of growth estimates and provider wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue shares generated across various type were further triangulated from other stakeholders.
Methodology Followed for Calculation of Market Shares:
• Market shares by type, by gender, by age groups, by diagnosis, by treatment, by drugs, by route of administration, by company and by each region were calculated based on the responses received through primary surveys with industry experts, in which the respondents were asked about the market shares or revenue generated from various types of leukemia therapeutics. The final shares were calculated by taking the geometric mean of the responses gathered from key opinion leaders after eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results inSPSS/Tableau Software.
• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast global leukemia therapeutics market, TechSci Research used various forecast techniques such as:
Moving Average
Time Series Analysis
Regression Analysis
Econometric and Judgmental Analysis
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used the impact analysis during short, medium and long term period to estimate the demand and to reach accurate market numbers. It should be noted that the figures compiled are only for the organized market including market share data. The currency used in the report is the United States Dollar (USD), with the market size indicated in USD million.
Partial List of Companies Interviewed Key Secondary Sources
Novartis AG AbbVie Inc. Roche Holding AG Amgen Inc. AstraZeneca PLC Pfizer Inc. Merck & Company Inc. Eli Lilly and Company Ltd. Bristol-Myers Squibb Company Gilead Sciences Inc. Astellas Pharma Inc. Takeda Pharmaceutical Company Ltd. Stemline Therapeutics Inc. iCell Gene therapeutics Otsuka Holdings Company Ltd.
World Bank International Monetary Fund (IMF) TechSci Research Proprietary Database &
Knowledge Repository Company Annual Reports Industry Magazines Industry Reports News Dailies Credible Paid Databases
21
Industry Brief
22
According to TechSci Research report, “Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Sex (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Company, By Region, Forecast & Opportunities, 2026”, the global leukemia therapeutics market is expected to grow at a formidable rate during the forecast period to reach USD7636.21 million on account of the increasing prevalence of leukemia. Furthermore, strong developing drug pipeline, increasing approvals of novel & innovative drugs and immunotherapies are projected to spur the market during forecast years. Moreover, technological advancements & innovations and faster approvals by the regulatory agencies are further creating lucrative opportunities for the market. However, lack of awareness among the population pertaining to the disease and its severity can hamper the growth of market during forecast period. Additionally, presence of generic drugs and limited availability of treatment options restrict the growth of market during the forecast period. Furthermore, lack of early diagnosis of the disease also obstructs the market growth over the next few years. Moreover, the high cost of treatments and associated adverse effects are further slowing down the growth of market.
The global leukemia therapeutics market is segmented based on type, gender, age groups, diagnosis, treatment, drugs, route of administration, country, company and region. Based on type, the market can be divided into chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and others. The chronic lymphocytic leukemia is expected to dominate the market on account of the large number of treatment options available and high incidence rate of chronic lymphocytic leukemia. Based on age groups, the market can be segmented into 0-15, 15-30, 30-50 and 50+. The 50+ years age group segment is expected to dominate the market since leukemia mostly affects the old age population. Based on sex, the market can be bifurcated into male and female. The male segment dominates the market since male population especially in their middle age are affected by this disease. Leukemia is often regarded as the most common type of cancer in males. Based on treatment, the market can be categorized into chemotherapy, stem cell transplantation, immunotherapy, targeted therapy and others. The chemotherapy segment is expected to dominate the market during forecast period due to its effectiveness in killing cancerous cells and inhibiting their proliferation and maintaining a normal level of lymphocytes. Additionally, increased survival rate of the patients treated with chemotherapy is again fueling the demand for the segment. The immunotherapy segment is expected to register the highest growth during the forecast period. Based on drug, the market can be segmented into antimetabolites, hormones (corticosteroids), tyrosine kinase inhibitors, monoclonal antibodies and others. The tyrosine kinase inhibitors hold the largest market share and this can be ascribed to their fewer side effects and higher efficacy.
Novartis AG, AbbVie Inc., Roche Holding AG, Amgen Inc., AstraZeneca PLC, Pfizer Inc., Merck & Company Inc., Eli Lilly and Company Ltd., Bristol-Myers Squibb Company, Gilead Sciences Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Stemline Therapeutics Inc., Icell Gene Therapeutics, Otsuka Holdings Company Ltd. are some of the leading players operating in global leukemia therapeutics market. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in May 2018, Novartis launched its CAR-T cell therapy for the second indication treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah CAR- T cell therapy, Novartis is now a pioneer of leukemia immunotherapies. Recently on February 2021, Novartis has received a designation from FDA for breakthrough therapy for ongoing investigations on STAMP inhibitor Asciminib (ABL001) for chronic myeloid leukemia.
“Asia-Pacific is expected to witness the highest growth in the leukemia therapeutics market during the forecast period on account of the increasing investments in research and development for the treatment of leukemia and the growing prevalence of leukemia in countries such as Japan and India. Additionally, the increasing disposable income of consumers and improving healthcare infrastructure in the region is further expected to propel the market during forecast period. Also, growing focus of market players on addressing healthcare-based demands in these countries is further expected to foster the growth of market through 2026.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
Sample Data - Snapshot
Global Leukemia Therapeutics Market Size, By Value (USD Million), 2016–2026F
2016 CAGR By Value
XX%2020 2021E
By Value (USD Million)
CAGR By Value
YY%2026F
5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%30% 20% 20% 10% 20%
2026F2025F2024F2023F2022F2021E20202019201820172016
Chronic Lymphocytic Leukemia Acute Lymphocytic Leukemia
Acute Myeloid Leukemia Chronic Myeloid Leukemia Others
Asia-Pacific Leukemia Therapeutics Market Share, By Type, By Value, 2016–2026F
2026F 40% 20% 20% 20%2025F 40% 20% 20% 20%2024F 40% 20% 20% 20%2023F 40% 20% 20% 20%2022F 40% 20% 20% 20%2021E 40% 20% 20% 20%2020 40% 20% 20% 20%2019 40% 20% 20% 20%2018 40% 20% 20% 20%2017 40% 20% 20% 20%2016 40% 20% 20% 20%
India Leukemia Therapeutics Market Share, By Diagnosis, By Value, 2016–2026F
Blood Test Biopsy Physical Exam Imaging
23
Report Ordering
Report Name: GLOBAL LEUKEMIA THERAPEUTICS MARKET
FORECAST & OPPORTUNITIES2016 – 2026
To View Sample OR Purchase Report
License Type Price
Single User License $4450
Multi-User License $5450
Custom Research License $9450
24
About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality reports. The proprietary forecasting models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the market.
Related Reports
• India Telemedicine Market By Component (Hardware, Software, Service (Tele Consulting, Tele Monitoring, Tele Education, Tele Training, Others)) By Deployment Mode (On-Premise, Cloud) By Type (Telehospitals, Telehomes, mHealth) By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Others) By End User (Hospitals, Clinics, Homecare) By Company, By Region, Forecast & Opportunities, FY2027
• Global Vital Signs Monitoring Devices Market By Product Type (Blood Pressure Monitors, Pulse Oximeters, Temperature Monitoring Devices) By End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care Centers, Others) By Region, Competition Forecast & Opportunities, 2026
TechSci Research – North America708 Third Avenue, Manhattan,
New York, United StatesTel: +1- 646- 360- 1656
Email: [email protected] www.techsciresearch.com
Disclaimer
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and firsthand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.
TechSci Research – Europe 54, Old brook, Bretton, Peterborough,
United KingdomEmail:
[email protected] www.techsciresearch.com
TechSci Research – Asia-PacificB – 44, Sector – 57, Noida, National
Capital Region, U.P. - IndiaTel: +91-120-4523900
Email: [email protected] www.techsciresearch.com